|
2025
|
G/S
|
Pharmaceutical preparations and substances in the field of neurodevelopmental and neurodegenerati... |
|
|
G/S
|
Pharmaceutical preparations and substances in the field of
neurodevelopmental and neurodegenerat... |
|
|
G/S
|
Financial and insurance consultation services, namely, patient advisory, support and consultancy ... |
|
|
G/S
|
Patient advisory, support and consultancy services regarding access to medical treatment of hered... |
|
|
G/S
|
Education and training services, namely, seminars, providing non-downloadable webinars, and works... |
|
|
Invention
|
Compounds and methods for reducing pln expression.
Provided are oligomeric compounds, methods, a... |
|
|
Invention
|
Compounds and methods for reducing kcnt1 expression.
Provided are compounds, methods, and pharma... |
|
|
G/S
|
Pharmaceutical preparations and substances for the treatment
of edema, namely hereditary angioed... |
|
|
G/S
|
Organizing and conducting support groups in the field of healthcare; Providing emotional counseli... |
|
|
G/S
|
Mobile healthcare services; Health care services, namely, providing disease and chronic condition... |
|
|
G/S
|
Providing on-line non-downloadable software for use in organizing, and conducting individual supp... |
|
|
Invention
|
Linkage modified oligomeric compounds.
The present invention provides gapped oligomeric compound... |
|
|
G/S
|
Pharmaceuticals for treatment of genetic diseases and
disorders; pharmaceuticals for treatment o... |
|
|
G/S
|
Pharmaceuticals for treatment of genetic diseases and disorders; pharmaceuticals for treatment of... |
|
|
G/S
|
Pharmaceutical preparations and substances for the treatment of edema, namely, hereditary angioed... |
|
|
G/S
|
Medical services; medical information services; providing a website featuring medical and healthc... |
|
|
Invention
|
Methods and compositions for modulating apolipoprotein (a) expression.
Disclosed herein are anti... |
|
|
Invention
|
Conjugated antisense compounds and their use.
The present disclosure provides half duplex compou... |
|
|
G/S
|
Pharmaceutical preparations and substances for the treatment of neurodevelopmental and neurodegen... |
|
|
Invention
|
Modulators of diacyglycerol acyltransferase 2 (dgat2).
The present embodiments provide methods, ... |
|
|
G/S
|
Education and medical training services, namely, providing seminars, non-downloadable webinars, a... |
|
|
G/S
|
Providing healthcare information, medical information, and pharmaceutical information online, by ... |
|
|
Invention
|
Compounds and methods for modulating scn2a.
Provided are compounds, methods, and pharmaceutical ... |
|
|
Invention
|
Conjugated antisense compounds for use in therapy.
Provided herein are methods of administering ... |
|
|
G/S
|
Pharmaceutical preparations and substances for the treatment of edema, namely hereditary angioede... |
|
2024
|
Invention
|
Nucleic acid binding agents and uses thereof. Provided are guided nucleic acid binding agents, sy... |
|
|
Invention
|
Conjugated antisense compounds and their use.
Provided herein are oligomeric compounds with conj... |
|
|
G/S
|
Patient advisory, support and consultancy services regarding access to medical treatment in the n... |
|
|
G/S
|
Providing pharmaceutical information regarding patient reimbursement for pharmaceuticals Providin... |
|
|
G/S
|
Providing financial information online and by telephone to patients, physicians, medical office s... |
|
|
G/S
|
Education and training services, namely, providing seminars, online non-downloadable webinars, an... |
|
|
Invention
|
Methods for treating hypercholesterolemia.
Disclosed herein are antisense compounds and methods ... |
|
|
Invention
|
Methods for reducing ataxin-2 expression.
Provided herein are methods for decreasing Ataxin-2 mR... |
|
|
Invention
|
Compounds and methods for reducing lrrk2 expression.
Provided are compounds, methods, and pharma... |
|
|
Invention
|
Modulation of gene expression. The present embodiments provide methods of modulating gene express... |
|
|
Invention
|
Compounds and methods for modulating acute activation. Provided herein are pharmaceutical composi... |
|
|
Invention
|
Compounds and methods for modulating atxn1.
Provided are compounds, methods, and pharmaceutical ... |
|
|
Invention
|
Methods for modulating ube3a-ats. Provided are methods of administering ION582 for reducing the a... |
|
|
Invention
|
Compounds and methods for modulating smn2.
Disclosed herein are compounds, compositions and meth... |
|
|
Invention
|
Modulators of apol1 expression.
The present embodiments provide methods, compounds, and composit... |
|
|
Invention
|
Methods and compositions for reducing angiotensinogen. Provided herein are methods of reducing th... |
|
|
Invention
|
Compounds and methods for modulating cln3 expression. Provided are compounds, methods, and pharma... |
|
|
Invention
|
Modulators of malat1 expression.
The present embodiments provide methods, compounds, and composi... |
|
|
Invention
|
Selective antisense compounds and uses thereof.
The present invention provides oligomeric compou... |
|
|
Invention
|
Cell-targeting complexes and uses thereof. Provided are complexes and methods for targeting cells... |
|
|
Invention
|
Compounds and methods for modulating ube3a-ats.
Provided are compounds, methods, and pharmaceuti... |
|
|
Invention
|
Compounds and methods for inhibiting lpa.
Provided are oligomeric duplexes, oligomeric compounds... |
|
|
Invention
|
Compounds and methods for inhibiting lpa. Provided are oligomeric duplexes, oligomeric compounds ... |
|
|
Invention
|
Compounds and methods for inhibiting lpa. Provided are oligomeric agents, methods, and pharmaceut... |
|
|
Invention
|
Compounds and methods for reducing apociii expression.
Provided are oligomeric agents, methods, ... |
|
|
Invention
|
Compounds and methods for reducing apociii expression. Provided are oligomeric agents, methods, a... |
|
|
Invention
|
Editing systems and components and uses thereof. Provided are guided nucleic acid binding agents,... |
|
|
Invention
|
Compounds and methods for reducing atn1 expression. Provided are oligomeric agents, methods, and ... |
|
|
Invention
|
Selective reduction of allelic variants.
Disclosed herein are antisense compounds and methods fo... |
|
|
Invention
|
Compounds and methods for reducing tubb4a expression. Provided are compounds, methods, and pharma... |
|
|
Invention
|
Modulation of alpha synuclein expression.
Disclosed herein are antisense compounds and methods f... |
|
|
Invention
|
Compounds and methods for the modulation of proteins.
In certain embodiments, the present disclo... |
|
|
Invention
|
Compounds and methods for modulation of dystrophia myotonica-protein kinase (dmpk) expression.
P... |
|
|
Invention
|
Methods and compositions for inhibiting pmp22 expression.
The present embodiments provide method... |
|
2023
|
Invention
|
Linkage modified oligomeric compounds and uses thereof.
The present disclosure provides oligomer... |
|
|
Invention
|
Methods for separating certain oligonucleotide compounds.
Provided are methods for reducing the ... |
|
|
Invention
|
Rnai agents of modulating plp1.
Provided are antisense agents, RNAi agents, pharmaceutical compo... |
|
2022
|
Invention
|
Compounds and methods for reducing glycogen synthase 1.
Provided are compounds, methods, and pha... |
|
|
Invention
|
Compounds and methods for reducing pcdh19 expression.
Provided are oligomeric agents, oligomeric... |
|
|
Invention
|
Compounds and methods for modulating glycogen synthase 1.
Provided are compounds, methods, and p... |
|
|
Invention
|
Compounds and methods for modulating progranulin expression.
Provided are oligomeric compounds, ... |
|
|
Invention
|
Compounds and methods for reducing tau expression.
Provided are RNAi agents, methods, and pharma... |
|
|
Invention
|
Compounds and methods for reducing dmpk expression.
Provided are oligomeric compounds, methods, ... |
|
|
Invention
|
Compounds and methods for reducing ifnar1 expression.
Provided are oligomeric agents, oligomeric... |
